Tripos Stock Surges 21 Percent on Extended Pfizer Deal

Nov 15, 2004

NEW YORK, Nov. 15 (GenomeWeb News) - Shares in Tripos were up 21 percent at $5.46 in mid-afternoon trading as investors cheered news of an extended multimillion-dollar software license agreement with Pfizer.

The companies initially announced a wide area network partnership in January 2001 that Pfizer employ a "broad array" of Tripos' drug-discovery software tools, including the SYBYL and UNITY programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Cloud Ready

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

The Science and Policy Connection

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

The New Yeast

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

This Week in Cell

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.

Main menu